
|Videos|May 16, 2017
Treating NSCLC Patients Without an Actionable Oncogenic Driver
Author(s)Sarah B. Goldberg, MD, MPH
Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































